Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Akt/mTOR protein kinase inhibitor Palomid 529, 5 mg  

Akt/mTOR protein kinase inhibitor Palomid 529, 5 mg

8-(1-hydroxyethyl)-2-methoxy-3-(4-methoxybenzyloxy)-6H-benzo[c]chromen-6-one

Palomid 529 is a protein kinase inhibitor targeting Akt/mTOR

More details

PKI-PALOM-005

Availability: within 3 days

136,50 €

Background: Palomid 529 is a small molecule kinase inhibitor, targeting Akt/mTOR; Dual TORC1/2 inhibitor of the PI3K/Akt//mTOR pathway having broad activity in angiogenesis and cellular proliferation; P529 inhibits cell growth of a broad spectrum of cancer cell lines. Palomid 529 inhibits both the mTORC1 and mTORC2 complexes, reduces phosphorylation of pAktS473, pGSK3βS9, and pS6 but no effect observed on pMAPK or pAktT308

Chemical formula: C24H22O6
Molecular weight: 406.43 g/mol
Purity: >98%
Solubility: Soluble in DMSO
Appearance: Light Brown Solid
CAS Number: 914913-88-5

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers. 

References

Q Xue et al. Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability. Cancer Res. 2008, 68(22), 9551-9557.

R Diaz et al. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Br. J. Cancer 2009, 100, 932–940.

GL Gravina et al. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. Endocr. Relat. Cancer. 2011, 18(4), 385-400.

Xue Q, et al. Cancer Res, 2008, 68(22), 9551-9557.